M&A - BioCorRx Inc.

Form Type: 8-K

Filing Date: 2025-03-11

Corporate Action: Acquisition

Type: New

Accession Number: 000147793225001603

Filing Summary: On March 4, 2025, BioCorRx Inc. entered into an Asset Purchase Agreement (APA) with its majority-owned subsidiary BioCorRx Pharmaceuticals, Inc. and USWM, LLC. As per the APA, BioCorRx Pharmaceuticals acquired specific assets and assumed certain liabilities related to Lucemyra, an FDA-approved medication for opioid withdrawal, for an upfront purchase price of $400,000. This amount will be satisfied through 50% of the net sales of Lucemyra and 50% of the net distributable profits of its generic version. Additionally, a Securities Purchase Agreement (SPA) was executed alongside the APA, wherein BioCorRx agreed to issue 500,000 shares of common stock and a warrant for the purchase of another 500,000 shares at $1.00 each, valid for two years. This acquisition aims to bolster BioCorRx's portfolio in the opioid addiction treatment market. A press release was issued on March 10, 2025, announcing the closure of these transactions.

Document Link: View Document